Abstract Body

Background: Rifampin(RIF) induces cytochrome P450 (CYP) isoforms, which can lower plasma EFV exposure. However, in STRIDE, RIF-containing tuberculosis therapy was associated with increased EFV Cmin. As CYP2B6 polymorphisms predict EFV exposure, we conducted a nested pharmacogenomics study to evaluate EFV Cmin by CYP2B metabolizer status in STRIDE participants. Methodology: EFV Cmin was measured by HPLC(LLQ = 0.1 μg/mL) in samples obtained 20-28 hours post-dose following no missed doses in prior 3 days(self report). CYP2B6 genotyping was by MassARRAY iPLEX Gold (Sequenom, Inc). Metabolizer status was defined by three CYP2B6 polymorphisms; 15582C→T, 516G→T, and 983T→C as follows: extensive =CC-GG-TT or CT-GG-TT; intermediate = TT-GG-TT, CC-GT-TT, CC-GG-TC, CT-GG-TC,or CTGT-TT; slow = CC-TT-TT, CC-GT-TC, or CC-GG-CC. Only subjects who consented for genetic testing under protocol A5243 were included. Results: 32 subjects with both on-RIF and off-RIF EFV Cmin values and CYP2B6 genotype were included from South Africa (12), Peru (12) and Uganda (8). Median age 31(IQR 22, 56), 15 male, race: 20 Black, 12 Hispanic. On-RIF Cmin was >1.0 μg/mL in 31; 1 was 0 μg/mL, likely spurious. Metabolizer status was slow (10), intermediate (13) and extensive (9). Of slow metabolizers, 5 had higher EFV Cmin on- vs. off-RIF; 2 had marked increases on- vs. off-RIF (11.3 and 9.7 μg/mL). On- and off-RIF medians (min, max) were 6.80 μg/mL(2.73, 21.34) vs. 5.43(3.20, 11.69). Of intermediate metabolizers, on- and off-RIF medians were 1.46 (0.05, 3.67) vs. 1.84 (1.00, 2.42). Of extensive metabolizers, on- and off-RIF medians were 1.40 (1.29, 2.65) vs. 1.65 (0.96, 2.94). Slow metabolizer Cmin were consistently elevated vs. intermediate and extensive metabolizers, both on- and off-RIF (Figure 1). Median within-subject differences in EFV Cmin (on- minus off- RIF) by haplotype were: slow 0.07 (range -1.93, 11.42), intermediate -0.01 (-1.78, 1.29) and extensive 0.01 (-0.33, 0.44). By metabolizer status, within-subject differences did not differ from zero by Wilcoxon signed rank nor between groups by rank-sum test. Conclusions: In a subset of STRIDE subjects genotyped for CYP2B6, slow metabolizer status was associated with high EFV concentrations off-RIF; 50% had even higher EFV Cmin on-RIF. This suggests that increased EFV Cmin with rifampin is driven in part by slow metabolism